How to Titrate Vasopressin
Vasopressin should be initiated at a fixed dose of 0.03 units/minute (not titrated) when added to norepinephrine in septic shock, or started at 0.01 units/minute in septic shock or 0.03 units/minute in post-cardiotomy shock with upward titration by 0.005 units/minute every 10-15 minutes until target MAP ≥65 mmHg is achieved.
Starting Dose and Initial Titration
The approach differs based on whether you're following guideline recommendations versus FDA labeling:
Guideline-Based Approach (Septic Shock)
Start vasopressin at a fixed dose of 0.03 units/minute 1. This is the Surviving Sepsis Campaign 2016 recommendation and represents the most widely accepted approach. Key points:
- Do not titrate - use as a fixed dose
- Add to norepinephrine (never use as sole initial vasopressor) 1
- Purpose: either raise MAP to target ≥65 mmHg OR decrease norepinephrine requirements 1
- Maximum recommended dose: 0.03-0.04 units/minute 1
FDA-Labeled Titration Protocol (Alternative Approach)
The FDA label provides a more granular titration strategy 2:
Septic Shock:
- Start: 0.01 units/minute
- Titrate up by 0.005 units/minute every 10-15 minutes
- Target: MAP ≥65 mmHg
- Maximum studied dose: 0.07 units/minute
Post-Cardiotomy Shock:
- Start: 0.03 units/minute
- Titrate up by 0.005 units/minute every 10-15 minutes
- Target: MAP ≥65 mmHg
- Maximum studied dose: 0.1 units/minute
Critical Dosing Boundaries
Never exceed 0.03-0.04 units/minute except as salvage therapy 1. Doses above this threshold should be reserved only for failure to achieve adequate MAP with other vasopressor agents 1. The evidence supporting higher doses is extremely limited 2, and adverse reactions increase substantially with escalating doses 2.
When to Add Vasopressin
Add vasopressin when norepinephrine requirements reach 0.25-0.50 µg/kg/min (base) after excluding persistent hypovolemia and cardiac dysfunction 3. This represents the optimal window for "decatecholaminization" - reducing catecholamine exposure while maintaining hemodynamic stability.
Weaning Strategy
After target blood pressure is maintained for 8 hours without catecholamines 2:
- Taper vasopressin by 0.005 units/minute every hour
- Titrate to maintain target blood pressure
- Monitor closely for hypotension during weaning
When vasopressin is combined with norepinephrine, reduce norepinephrine first to approximately 0.2 µg/kg/min, then withdraw vasopressin in small decremental steps according to MAP response 4.
Common Pitfalls and Caveats
Do not use vasopressin as monotherapy for initial treatment of sepsis-induced hypotension 1. Vasopressin alone decreases cardiac index, compromises oxygen delivery, and increases pulmonary vascular resistance 5. It must always be combined with norepinephrine.
Avoid premature escalation beyond 0.03-0.04 units/minute. The fixed-dose approach at 0.03 units/minute achieves MAP ≥70 mmHg in most patients within 1 hour, similar to titrated catecholamines 6. Escalating doses increases risk without clear benefit.
Monitor for digital/mesenteric ischemia, bradycardia, and decreased cardiac output 2. These are the most common adverse effects and may necessitate dose reduction or discontinuation.
Ensure adequate fluid resuscitation first. Vasopressin should only be initiated after appropriate volume loading, as it does not address hypovolemia and may worsen tissue perfusion in volume-depleted states 1.
Practical Algorithm
- Confirm shock state: Hypotension despite adequate fluid resuscitation (minimum 30 mL/kg crystalloid) 1
- Start norepinephrine first as primary vasopressor, targeting MAP ≥65 mmHg 1
- Add vasopressin at 0.03 units/minute when norepinephrine reaches 0.25-0.50 µg/kg/min 3
- Adjust norepinephrine (not vasopressin) to achieve MAP target
- Maintain vasopressin at fixed dose unless using FDA titration protocol for specific indications
- Wean norepinephrine first once hemodynamics stabilize
- Taper vasopressin last by 0.005 units/minute hourly after 8 hours of stability 2
The evidence strongly supports using vasopressin as a fixed-dose adjunct rather than a titratable primary vasopressor, which distinguishes it from catecholamine management strategies.